Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences, Inc. by Quarter
Alpine Immune Sciences, Inc. (CIK 0001626199, acquired May 2024 for povetacicept, $4.9B) — Pre-acquisition R&D expense ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences, Inc.: $22.5M in Q1 2024, up 14.7% from a year earlier. No newer figure appears in the documents we track.
Where the Q1 2024 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences, FY2018–FY2024Q1 pre-acquisition).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences, Inc. (CIK 0001626199, acquired May 2024 for povetacicept, $4.9B) — Pre-acquisition R&D expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2024 | Mar 31, 2024 | 22.5 | +14.7% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 22.9 | +22.3% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 19.2 | +8.9% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 19.2 | +9.4% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 19.6 | +20.0% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 18.8 | +22.1% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 17.6 | -3.9% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 17.6 | +20.2% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 16.3 | +56.2% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 15.4 | +69.9% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 18.3 | +197.2% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 14.6 | +106.1% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 10.4 | +113.9% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 9.04 | +55.9% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 6.16 | -35.4% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 7.10 | -30.2% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 4.88 | -52.9% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 5.80 | -35.1% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 9.53 | -9.5% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 10.2 | +77.8% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 10.4 | +173.1% | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 8.93 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 10.5 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | 5.72 | – | SEC Filing ↗ |
| Q1 2018 | Mar 31, 2018 | 3.79 | – | SEC Filing ↗ |
Breakdown
What makes up alpine Immune Sciences, Inc.
- Alpine Immune Sciences — Collaboration revenue ($M)7.03 · Q1 2024
- Alpine Immune Sciences — General and administrative expense ($M)7.27 · Q1 2024
- Alpine Immune Sciences — Total operating expenses ($M)29.7 · Q1 2024
- Alpine Immune Sciences — Operating income (loss) ($M)-22.7 · Q1 2024
- Alpine Immune Sciences — Net income (loss) ($M)-17.9 · Q1 2024
- Alpine Immune Sciences — Stock-based compensation expense ($M)3.99 · Q1 2024
- Alpine Immune Sciences — Cash and cash equivalents ($M)33.0 · Q1 2024
- Alpine Immune Sciences — Marketable securities ($M)273 · Q1 2024
- Alpine Immune Sciences — Total assets ($M)374 · Q1 2024
- Alpine Immune Sciences — Total liabilities ($M)40.9 · Q1 2024
- Alpine Immune Sciences — Stockholders' equity ($M)333 · Q1 2024
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences, Inc. ($M), quarterly Q1 2018–Q1 2024 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-rd-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.